Product Description
Mechanisms of Action: IL2 Agonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mabwell (Shanghai) Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
8MW2311-2022-CP101 | P2 |
Suspended |
Oncology Solid Tumor Unspecified |
2026-03-01 |